| Popis: |
Purpose To evaluate and compare the efficacy and safety of pemafibrate, a selective peroxisome proliferator-activator α modulator, with fenofibrate and bezafibrate, classical fibrates, in a real-world setting in patients with hypertriglyceridemia and type 2 diabetes (T2D). Methods 200 patients with hypertriglyceridemia (> 175 mg/dL) and T2D were studied. Adjusted least square mean percentage changes in serum levels of triglyceride (TG), transaminases, γ-glutamyl transpeptidase (γGTP), and creatinine kinase (CK) levels, and estimated glomerular filtration rates (eGFRs) were compared before and after 3-month therapy with pemafibrate 0.1 mg and 0.2 mg, fenofibrate 160 mg, and bezafibrate 400 mg. Multivariate logistic regression analyses were performed to examine the association between the fibrate therapy and achievement of TG target levels ( |
